Naloxone Hcl Spray
Product Images NDC 51662-1620

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Naloxone Hcl (NDC 51662-1620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pback (51662 1620 1 Package Label Back 3 1)

This is a prescription-only nasal spray called Naloxone HCI EX1T3 containing 4 mg of naloxone HCI (equivalent to 3.6 mg naloxone) in 0.1 mL spray. It is intended for use in the nose only and should be stored below 77°F (25°C) but excursions permitted up to 104°F (40°C). The product is not to be exposed to excessive heat above 104°F (40°C) and should be protected from light. It is meant to be used for known or suspected opioid overdose in adults and children. This product is manufactured in Israel by Perrigo and distributed by Perrigo® in Allegan, Michigan. Instructions for use are included in the enclosed Quick Start Guide.*

FDA Label Image

Front (51662 1620 1 Package Label Front)

FDA Label Image

S1 (51662 1620 1 Serialized Label)

FDA Label Image

Carton (51662 1620 2 Carton Labeling)

FDA Label Image

Back (51662 1620 2 Individual Package Label Back)

FDA Label Image

Front (51662 1620 2 Individual Package Label Front)

This is a product that is intended for use only in the nose, as indicated by the text "FOR USE IN THE NOSE ONLY". The product has an NDC number of 45802-811-00. The remaining text contains some characters that could not be identified or translated, so it is not available for description.*

FDA Label Image

Serialized (51662 1620 2 Serialized Labeling)

FDA Label Image

Clinical P 1 (Clinical 1)

This is a table of pharmacokinetic parameters of Naloxone, which compares the results of two different administration methods (nasal spray and intramuscular injection) and different doses. It shows data on the maximum concentration reached in the blood, the time it takes to reach this maximum concentration, the half-life of the drug, and the dose-normalized relative bioavailability. The data is presented for healthy subjects and measured in ng/mL, hr ng/mL, and percentage.*

FDA Label Image

Clinical P2 (Clinical 2)

FDA Label Image

I1 (Instruction 1)

FDA Label Image

I2 (Instruction 2)

FDA Label Image

I3 (Instruction 3)

FDA Label Image

I4 (Instruction 4)

FDA Label Image

I5 (Instruction 5)

FDA Label Image

Or1a (Ori 1a)

This text is a product label for a nasal spray containing Naloxone HCI, which is used in case of overdose response. It contains warnings to only use in the nose and to check the expiration date. There is a quick start guide included and the product comes in a two-pack.*

FDA Label Image

1bb (Ori 1bb)

This appears to be a product description for a Naloxone Hydrochloride Nasal Spray used for overdoses of opioid drugs. The packaging includes instructions for use, warnings about not testing devices or using expired product, and contact information for additional information. There are also references to dosage amounts and potential side effects.*

FDA Label Image

Ori1aa (Ori1aa)

The text is not readable ( error).*

FDA Label Image

Ori1b (Ori1b)

FDA Label Image

Q1 (Quick 1)

FDA Label Image

Q2 (Quick 2)

FDA Label Image

Q3 (Quick 3)

This is a list of two mechanical parts, a nozzle and a plunger. No additional information is provided.*

FDA Label Image

Q4 (Quick 4)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.